NMN ⇒ Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule

[daviddean]

Another interesting study on the NMN therapeutic potential:

"NMN could open up a new horizon in modern therapeutics. This biomolecule has demonstrated numerous beneficial pharmacological activities in several preclinical disease models including myocardial and cerebral ischemia, neurodegenerative disorders like Alzheimer’s disease, and diabetes. The most recent discovery of its anti-ageing, life-span prolonging property in the murine model has made NMN more attractive as a potential therapeutic candidate. Most of its pharmacological actions take place by facilitating NAD+ synthesis, as direct NAD+ administration in higher dose exhibits side effects like insomnia, fatigue, and anxiety sometimes and it has poor penetration capability through plasma membrane compared to NMN."

Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule.
Poddar S, Sifat A, Haque S, Nahid N, Chowdhury S, Mehedi I.
Biomolecules. 2019 Jan 21;9(1). pii: E34. doi: 10.3390/biom9010034.
Full study HERE:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359187/

[NewLifeScience]

I understand there are 4 major studies and human trials going on right now, that will be a big leap forward in substantiating things considerably.

Does anyone know the timeline for these major human trials?

[Fred]

Three of those four trials are looking at safety and pharmacokinetics, one of those three will also be looking at hormones.

The fourth trial is looking at insulin-sensitivity and beta-cell function in pre-diabetic elderly women aged 55-75 taking 250 mg NMN.

The doses listed in these small safety and efficacy trials are 100, 200 and 250 mg NMN.

No timelines for publication of any of these are known yet.

I posted them here:
viewtopic.php?f=7&t=1140

EDIT: the first single administration safety trial of oral NMN in 10 Japanese men has now been published: viewtopic.php?f=7&t=1181